Compile Data Set for Download or QSAR
Report error Found 34 Enz. Inhib. hit(s) with all data for entry = 10299
TargetTyrosine-protein kinase BTK(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525847(US11174254, Compound G-8)
Affinity DataIC50: 9nMAssay Description:The compound was predissolved in 100% DMSO.10 mM drug stock solution was obtained by dissolution at room temperature and then gradiently diluted with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525843(US11174254, Compound G-4)
Affinity DataIC50: 10nMAssay Description:The compound was predissolved in 100% DMSO.10 mM drug stock solution was obtained by dissolution at room temperature and then gradiently diluted with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525845(US11174254, Compound G-6)
Affinity DataIC50: 14nMAssay Description:The compound was predissolved in 100% DMSO.10 mM drug stock solution was obtained by dissolution at room temperature and then gradiently diluted with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525846(US11174254, Compound G-7)
Affinity DataIC50: 19nMAssay Description:The compound was predissolved in 100% DMSO.10 mM drug stock solution was obtained by dissolution at room temperature and then gradiently diluted with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525841(US11174254, Compound G-2)
Affinity DataIC50: 25nMAssay Description:The compound was predissolved in 100% DMSO.10 mM drug stock solution was obtained by dissolution at room temperature and then gradiently diluted with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525855(US11174254, Compound G-16)
Affinity DataIC50: 44nMAssay Description:The compound was predissolved in 100% DMSO.10 mM drug stock solution was obtained by dissolution at room temperature and then gradiently diluted with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525850(US11174254, Compound G-11)
Affinity DataIC50: 48nMAssay Description:The compound was predissolved in 100% DMSO.10 mM drug stock solution was obtained by dissolution at room temperature and then gradiently diluted with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525854(US11174254, Compound G-15)
Affinity DataIC50: 52nMAssay Description:The compound was predissolved in 100% DMSO.10 mM drug stock solution was obtained by dissolution at room temperature and then gradiently diluted with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525848(US11174254, Compound G-9)
Affinity DataIC50: 55nMAssay Description:The compound was predissolved in 100% DMSO.10 mM drug stock solution was obtained by dissolution at room temperature and then gradiently diluted with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525842(US11174254, Compound G-3)
Affinity DataIC50: 58nMAssay Description:The compound was predissolved in 100% DMSO.10 mM drug stock solution was obtained by dissolution at room temperature and then gradiently diluted with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525853(US11174254, Compound G-14)
Affinity DataIC50: 59nMAssay Description:The compound was predissolved in 100% DMSO.10 mM drug stock solution was obtained by dissolution at room temperature and then gradiently diluted with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525852(US11174254, Compound G-13)
Affinity DataIC50: 63nMAssay Description:The compound was predissolved in 100% DMSO.10 mM drug stock solution was obtained by dissolution at room temperature and then gradiently diluted with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525849(US11174254, Compound G-10)
Affinity DataIC50: 68nMAssay Description:The compound was predissolved in 100% DMSO.10 mM drug stock solution was obtained by dissolution at room temperature and then gradiently diluted with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525840(US11174254, Compound G-1)
Affinity DataIC50: 141nMAssay Description:The compound was predissolved in 100% DMSO.10 mM drug stock solution was obtained by dissolution at room temperature and then gradiently diluted with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525844(US11174254, Compound G-5)
Affinity DataIC50: 156nMAssay Description:The compound was predissolved in 100% DMSO.10 mM drug stock solution was obtained by dissolution at room temperature and then gradiently diluted with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525851(US11174254, Compound G-12)
Affinity DataIC50: 1.35E+3nMAssay Description:The compound was predissolved in 100% DMSO.10 mM drug stock solution was obtained by dissolution at room temperature and then gradiently diluted with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525851(US11174254, Compound G-12)
Affinity DataIC50: 1.53E+3nMAssay Description:The inhibitory activity of compounds to be tested on wild-type EGFR kinase (Invitrogen, PV3872) was measured by z-lyte methods.The working concentrat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525853(US11174254, Compound G-14)
Affinity DataIC50: 2.69E+3nMAssay Description:The inhibitory activity of compounds to be tested on wild-type EGFR kinase (Invitrogen, PV3872) was measured by z-lyte methods.The working concentrat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525845(US11174254, Compound G-6)
Affinity DataIC50: 3.00E+3nMAssay Description:The inhibitory activity of compounds to be tested on wild-type EGFR kinase (Invitrogen, PV3872) was measured by z-lyte methods.The working concentrat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525843(US11174254, Compound G-4)
Affinity DataIC50: 3.00E+3nMAssay Description:The inhibitory activity of compounds to be tested on wild-type EGFR kinase (Invitrogen, PV3872) was measured by z-lyte methods.The working concentrat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525852(US11174254, Compound G-13)
Affinity DataIC50: 3.08E+3nMAssay Description:The inhibitory activity of compounds to be tested on wild-type EGFR kinase (Invitrogen, PV3872) was measured by z-lyte methods.The working concentrat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525854(US11174254, Compound G-15)
Affinity DataIC50: 4.27E+3nMAssay Description:The inhibitory activity of compounds to be tested on wild-type EGFR kinase (Invitrogen, PV3872) was measured by z-lyte methods.The working concentrat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525841(US11174254, Compound G-2)
Affinity DataIC50: 4.69E+3nMAssay Description:The inhibitory activity of compounds to be tested on wild-type EGFR kinase (Invitrogen, PV3872) was measured by z-lyte methods.The working concentrat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525848(US11174254, Compound G-9)
Affinity DataIC50: 5.03E+3nMAssay Description:The inhibitory activity of compounds to be tested on wild-type EGFR kinase (Invitrogen, PV3872) was measured by z-lyte methods.The working concentrat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525855(US11174254, Compound G-16)
Affinity DataIC50: 5.68E+3nMAssay Description:The inhibitory activity of compounds to be tested on wild-type EGFR kinase (Invitrogen, PV3872) was measured by z-lyte methods.The working concentrat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525847(US11174254, Compound G-8)
Affinity DataIC50: 6.42E+3nMAssay Description:The inhibitory activity of compounds to be tested on wild-type EGFR kinase (Invitrogen, PV3872) was measured by z-lyte methods.The working concentrat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525846(US11174254, Compound G-7)
Affinity DataIC50: 6.99E+3nMAssay Description:The inhibitory activity of compounds to be tested on wild-type EGFR kinase (Invitrogen, PV3872) was measured by z-lyte methods.The working concentrat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525844(US11174254, Compound G-5)
Affinity DataIC50: 7.85E+3nMAssay Description:The inhibitory activity of compounds to be tested on wild-type EGFR kinase (Invitrogen, PV3872) was measured by z-lyte methods.The working concentrat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525840(US11174254, Compound G-1)
Affinity DataIC50: 9.27E+3nMAssay Description:The inhibitory activity of compounds to be tested on wild-type EGFR kinase (Invitrogen, PV3872) was measured by z-lyte methods.The working concentrat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525850(US11174254, Compound G-11)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibitory activity of compounds to be tested on wild-type EGFR kinase (Invitrogen, PV3872) was measured by z-lyte methods.The working concentrat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525849(US11174254, Compound G-10)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibitory activity of compounds to be tested on wild-type EGFR kinase (Invitrogen, PV3872) was measured by z-lyte methods.The working concentrat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525842(US11174254, Compound G-3)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibitory activity of compounds to be tested on wild-type EGFR kinase (Invitrogen, PV3872) was measured by z-lyte methods.The working concentrat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525856(US11174254, Compound G-17)
Affinity DataIC50: 1.00E+4nMAssay Description:The compound was predissolved in 100% DMSO.10 mM drug stock solution was obtained by dissolution at room temperature and then gradiently diluted with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Yangtze River Pharmaceutical Group

US Patent
LigandPNGBDBM525856(US11174254, Compound G-17)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibitory activity of compounds to be tested on wild-type EGFR kinase (Invitrogen, PV3872) was measured by z-lyte methods.The working concentrat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent